NCT06682481 is a clinical trial of Measurement of biomarker in Obesity, Childhood, sponsored by Philippe Klee, MD-PhD.

Who is sponsoring NCT06682481?

NCT06682481 is sponsored by Philippe Klee, MD-PhD.

What drugs are being tested in NCT06682481?

Interventions in NCT06682481: Measurement of biomarker.

What condition does NCT06682481 study?

NCT06682481 studies Obesity, Childhood, Type 2 Diabetes Mellitus in Obese.

Is NCT06682481 still recruiting?

NCT06682481 is currently recruiting now. Last updated 2 April 2025.

Last reviewed 2025-04-02 · How we verify

NCT06682481

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function

Recruiting now Last updated 2 April 2025

What this trial tests

trial testing Measurement of biomarker in Obesity, Childhood in 50 participants. Currently enrolling.

Timeline

22 November 2024

Primary endpoint
31 December 2028

31 December 2028

Quick facts

Lead sponsor	Philippe Klee, MD-PhD
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	50
Start date	22 November 2024
Primary completion	31 December 2028
Estimated completion	31 December 2028
Sites	1 location across Switzerland

Drugs / interventions tested

Measurement of biomarker

Conditions studied

Obesity, Childhood — all drugs for Obesity, Childhood →
Type 2 Diabetes Mellitus in Obese — all drugs for Type 2 Diabetes Mellitus in Obese →

Sponsor

Philippe Klee, MD-PhD

Who can join

Adults 12 to 16, any sex, with Obesity, Childhood or Type 2 Diabetes Mellitus in Obese. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obesity, Childhood

Currently open trials in the same condition.

NCT06810557 — Brief Behavioral Sleep Intervention for Obesity Prevention in Primary Care · NA · recruiting
NCT06892483 — Breastmilk in Response to a Bout of Exercise · recruiting
NCT06464497 — Whole Foods for Teens: A Pilot Dietary Intervention to Reduce Body Adiposity in Adolescents With Obesity · NA · recruiting
NCT06847373 — Efficacy and Safety of Vitamin D Supplementation in Pediatric Patients with Obesity · NA · recruiting
NCT06579079 — Improving Participation in Universal School Meals (USM) · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06682481 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Philippe Klee, MD-PhD
Last refreshed: 2 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06682481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing